Interview with Marisa Sanvito, Senior Director, Quintiles Brazil
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
Address: Praia de Botafogo 501 1° Andar Bloco Corcovado 22250-040 Rio de Janeiro – RJ,Brazil
Tel: 55 21 3266 6200
Web: http://www1.actelion.com.br/br/index.page
In 2002, Actelion opened its first office in Latin America. Brazil was chosen as the venue due to different factors. The country is a medical centre in the region and is endowed with considerable structure, hospital and medical science. Brazil also possesses a strong political and social framework and is projected to be an important partner in international decisions, not only due its specific significance, such as increasing the performance of its economy.
In addition, it has development programs and conducts scientific and technological research.
Due to its growth potential in pharmaceuticals and its status as one of the largest research centers of reference in the continent, Brazil was chosen to as base of operations for Actelion in Latin America.
Tracleer, Zavesca
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with the regulatory picture. In…
Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to sell pharmaceuticals, or the…
See our Cookie Privacy Policy Here
